The Effects of Dermatan Sulfate at Submicrogram/ml Concentrations on In Vitro Thrombin Generation

Summary

Dermatan sulfate is an antithrombotic glycosaminoglycan which has been shown to be effective in preventing deep venous thrombosis in general surgery patients when present at concentrations less than 1 |ig/ml. It has also been found to circulate physiologically in similar concentrations in pregnant women at term and in cord blood. We investigated the ability of dermatan sulfate added to plasma at 0.2, 0.5 and 1.0 μg/ml to inhibit thrombin generation initiated by low concentrations of recombinant human tissue factor in defibrinated plasma. A dose dependent decrease in thrombin potential was demonstrated at therapeutically relevant concentrations of dermatan sulfate (0.5 and 1.0 μg/ml) but there was no induction of a lag phase in thrombin generation. We were unable to demonstrate a significant effect on thrombin potential of dermatan sulfate at a concentration similar to that found in pregnancy plasma (0.2 μg/ml). This indicates that either the dermatan sulfate concentration found in pregnancy plasma is not physiologically relevant or that our experimental system (which lacks platelets and fibrin) does not accurately reflect physiologic conditions. The effect on the thrombin potential was somewhat greater at the lowest concentration of tissue factor and amounted to a maximum inhibition of approximately 50% at 1 μg/ml dermatan sulfate. A dose dependent increase in formation of thrombin-heparin cofactor II complexes and a decrease in thrombin-antithrombin complex formation with increasing dermatan sulfate concentration were observed at all dermatan sulfate concentrations. Prothrombin consumption was not changed by any dose of dermatan sulfate. We conclude that dermatan sulfate, at the concentrations tested, catalyses inhibition of free thrombin by heparin cofactor II but not efficiently enough to inhibit prothrombinase formation.

• References

• 1 Tollefsen DM, Pestka CA, Monafo WJ. Activation of heparin cofactor II by dermatan sulfate. J Biol Chem 1983; 258: 6713-6716
• 2 Rosenberg RD, Armand G, Lam L. Structure-function relationships of heparin species. Proc Natl Acad Sci USA 1978; 75: 3065-3069
• 3 Bendayan P, Boccalon H, Dupouy D, Boneu B. Dermatan sulfate is a more potent inhibitor of clot-bound thrombin than unfractionated and low molecular weight heparins. Thromb Haemost 1994; 71: 576-580
• 4 Fernandez F, Van Ryn J, Ofosu FA, Hirsh J, Buchanan MR. The haemor-rhagic and antithrombotic effects of dermatan sulfate. Br J Haematol 1986; 64: 309-317
• 5 Maggi A, Abbadini M, Pagella PG, Borowska A, Pangrazzi J, Donati MB. Antithrombotic properties of dermatan sulphate in a rat venous thrombosis model. Haemost 1987; 17: 329-335
• 6 Merton RE, Thomas DP. Experimental studies on the relative efficacy of dermatan sulphate and heparin as antithrombotic agents. Thromb Haemost 1987; 58: 839-842
• 7 Agnelli G, Cosmi B, Di Fillipo P, Ranucci V, Veschi F, Longetti M, Renga C, Barzi F, Gianese F, Lupattelli L, Rinonapeli E, Nenci GG. A randomized, double-blind, placebo-controlled trial of dermatan sulfate for prevention of deep vein thrombosis in hip fracture. Thromb Haemost 1992; 67: 203-208
• 8 Prandoni P, Meduri F, Cuppini S, Toniato A, Zangrandi F, Polistena P, Gianese F, Maffei FaccioliA. Dermatan sulfate: a safe approach to prevention of postoperative deep vein thrombosis. Br J Surg 1992; 79: 505-509
• 9 Ryan KE, Lane DA, Flynn A, Ireland H, Boisclair M, Shepperd J, Curtis JR. Antithrombotic properties of dermatan sulphate (MF 701) in haemodialysis for chronic renal failure. Thromb Haemost 1992; 68: 563-569
• 10 Cohen AT, Phillips MJ, Edmondson RA, Skinner JA, Das SK, Cooper DJ, Thomas EM, Melissari E, Kakkar VV. A dose ranging study to evaluate dermatan sulphate in preventing deep vein thrombosis following total hip arthroplasty. Thromb Haemost 1994; 72: 793-798
• 11 Andrew M, Mitchell L, Berry L, Paes B, Delorme M, Ofosu F, Burrows R, Khambalia B. An anticoagulant dermatan sulfate proteoglycan circulates in the pregnant women and her fetus. J Clin Invest 1992; 89: 321-326
• 12 Delorme MA, Saeed N, Sevcik A, Mitchell L, Berry L, Johnston M, Andrew M. Plasma dermatan sulfate proteolgycan in a patient on chronic hemodialysis. Blood 1993; 82: 3380-3385
• 13 Liu L, Dewar L, Song Y, Kulczycky M, Blajchman MA, Fenton JW, Andrew M, Delorme M, Ginsberg J, Freissner KT, Ofosu FA. Inhibition of thrombin by antithrombin III and heparin cofactor II in vivo. Thromb Haemost 1995; 73: 405-412
• 14 Griffith MJ, Noyes CM, Church FC. Reactive site peptide structural similarity between heparin cofactor II and antithrombin III. J Biol Chem 1985; 260: 2218-2225
• 15 Ofosu FA, Hirsh J, Esmon CT, Modi GJ, Smith LM, Anvari N, Buchanan MR, Fenton JW, Blajchmann MA. Unfractionated heparin inhibits thrombin-catalysed amplification reactions of coagulation more efficiently than those catalysed by factor Xa. Biochem J 1989; 257: 143-150
• 16 Hemker HC, Wielders S, Beguin S. In: Fraxiparine Bounameaux H, Samama M, ten Cate JW. (eds). Stuttgart; Schattauer: 1990: 89
• 17 Hemker HC, Willems GM, Beguin S. A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. Thromb Haemost 1986; 56: 9-17
• 18 Delorme MA, Burrows RF, Ofosu FA, Andrew M. Thrombin regulation in mother and fetus during pregnancy. Sem Thromb Hemost 1992; 18: 81-90
• 19 de Boer K, ten Cate JW, Sturk A, Borm JJJ, Treffers PE. Enhanced thrombin generation in normal and hypertensive pregnancy. Am J Obstet Gynecol 1989; 160: 95-100
• 20 Weiner CP, Kwaan HC, Hauck WW, Duboe FJ, Paul M, Wallemark C-B. Fibrin generation in normal pregnancy. Obstet Gynecol 1984; 64: 46-48
• 21 Marler RA, Kleiss AJ, Griffin JH. An alternative extrinsic pathway of human blood coagulation. Blood 1982; 6: 1353-1358
• 22 Østerud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA 1977; 74: 5260-5264
• 23 Lawson JH, Kalafatis M, Stram S, Mann KG. A model for the tissue factor pathway to thrombin I. An empirical study. J Biol Chem 1994; 269: 23357-23366
• 24 Bar-Shavit R, Eldor A, Vlodavsky I. Binding of thrombin to subendothelial extracellular matrix: protection and expression of functional properties. J Clin Invest 1989; 84: 1096-1104
• 25 Lindhout T, Blezer R, Hemker HC. The anticoagulant mechanism of action of recombinant hirudin (CGP 39393) in plasma. Thromb Haemost 1990; 64: 464-468
• 26 Kumar R, Beguin S, Hemker HC. The influence of fibrinogen and fibrin on thrombin generation - evidence for feedback activation of the clotting system by clot bound thrombin. Thromb Haemost 1994; 72: 713-721
• 27 Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-391
• 28 Okwusidi JI, Anvari N, Kulczycky M, Blajchman MA, Buchanan MR, Ofosu FA. Fibrin moderates the catalytic action of heparin but not that of dermatan sulfate on thrombin inhibition in human plasma. J Lab Clin Med 1991; 117: 359-364
• 29 Beguin S, Lindhout T, Hemker HC. The effect of trace amounts of tissue factor on thrombin generation in platelet rich plasma, its inhibition by heparin. Thromb Haemost 1989; 61: 25-29
• 30 Handin RI, Cohen HJ. Purification and binding properties of human platelet factor four. J Biol Chem 1976; 251: 4273-4282